Drugs.com - Clinical Trials

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant...

Mar 12, 2025 - 06:23
 0
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
NEW HAVEN, Conn. and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant...
Read More

Tags:

Previous Article

Best Free Streaming Sites to Watch Movies and Sports in 2025

Next Article

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Related Posts

Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301

Cingulate Reports Safety Results from Final Phase 3 Tri...

Mar 5, 2025  0

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Co...

Feb 9, 2025  0

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Boehringer Provides Update on Iclepertin Phase III Prog...

Feb 9, 2025  0